Skip to content

Biolinq

Wearable glucose sensor patch for people with diabetes

Raised to date

$90M

of $100M offered across 1 Form D filing

Still open
$10M
Investors
45
Last filed
Mar 21, 2025

About

Biolinq Inc. is a pioneering healthcare technology company focused on enhancing metabolic health monitoring through innovative wearable biosensors. The company's flagship product, a continuous glucose monitoring (CGM) system, aims to provide a simpler and more accessible alternative to traditional glucose monitoring solutions, significantly improving the lives of people with diabetes.

Biolinq stands out by offering a less invasive, needle-free continuous glucose monitoring solution that integrates real-time activity tracking, enhancing user experience and engagement.

Funding

  • EquityFiled Mar 21, 2025Form D
    $90M/ $100M

Product

Continuous Glucose Monitoring System

Health Monitoring

Biolinq's continuous glucose monitoring system is a state-of-the-art wearable patch that harnesses the power of tiny electrochemical sensors to non-invasively measure glucose levels from the intradermal space beneath the skin. It provides users with real-time insights into their glucose levels while simultaneously monitoring their activity levels, all through a user-friendly interface.

  • Needle-free application for ease of use
  • Secure placement on the upper forearm for convenience
  • Real-time glucose monitoring for immediate awareness

Built for

Individuals with diabetes, specifically Type 2 diabetes

People on file